Viela Bio

$37.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.39 (+3.82%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours

Why Robinhood?

You can buy or sell Viela Bio and other stocks, options, and ETFs commission-free!

About VIE

Viela Bio, Inc. Common Stock, also called Viela Bio, is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. The listed name for VIE is Viela Bio, Inc. Common Stock.

CEO
Zheng Bin Yao
Employees
139
Headquarters
Gaithersburg, Maryland
Founded
2017
Market Cap
2.07B
Price-Earnings Ratio
Dividend Yield
Average Volume
142.43K
High Today
$38.97
Low Today
$36.02
Open Price
$36.66
Volume
92.19K
52 Week High
$70.66
52 Week Low
$23.69

Collections

VIE Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 24, After Hours

You May Also Like